Drug Profile
Research programme: Shigella vaccines - EndoBiologics/PATH
Latest Information Update: 10 Oct 2013
Price :
$50
*
At a glance
- Originator EndoBiologics
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Shigella infections
Most Recent Events
- 16 Aug 2013 Endobiologics files for Chapter 7 bankruptcy
- 16 Aug 2013 Discontinued - Preclinical for Shigella infections in USA (unspecified route)
- 20 Aug 2008 Preclinical trials in Shigella infections in USA (unspecified route)